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Abstract
Context: Women with polycystic ovary syndrome (PCOS) have an increased risk of 
cardiovascular disease (CVD), and biomarkers can be used to detect early subclinical 
CVD. Midregional-pro-adrenomedullin (MR-proADM), midregional-pro-atrial natriuretic 
peptide (MR-proANP) and copeptin are all associated with CVD and part of the delicate 
system controlling fluid and hemodynamic homeostasis through vascular tonus and 
diuresis. The GLP-1 receptor agonist liraglutide, developed for treatment of type 2 
diabetes (T2D), improves cardiovascular outcomes in patients with T2D including a 
decrease in particular MR-proANP.
Objective: To investigate if treatment with liraglutide in women with PCOS reduces 
levels of the cardiovascular biomarkers MR-proADM, MR-proANP and copeptin.
Methods: Seventy-two overweight women with PCOS were treated with 1.8 mg/
day liraglutide or placebo for 26 weeks in a placebo-controlled RCT. Biomarkers, 
anthropometrics, insulin resistance, body composition (DXA) and visceral fat (MRI) were 
examined.
Results: Baseline median (IQR) levels were as follows: MR-proADM 0.52 (0.45–0.56) nmol/L, 
MR-proANP 44.8 (34.6–56.7) pmol/L and copeptin 4.95 (3.50–6.50) pmol/L. Mean 
percentage differences (95% CI) between liraglutide and placebo group after treatment 
were as follows: MR-proADM −6% (−11 to 2, P = 0.058), MR-proANP −25% (−37 to −11, 
P = 0.001) and copeptin +4% (−13 to 25, P = 0.64). Reduction in MR-proANP concentration 
correlated with both increased heart rate and diastolic blood pressure in the liraglutide 
group. Multiple regression analyses with adjustment for BMI, free testosterone, insulin 
resistance, visceral fat, heart rate and eGFR showed reductions in MR-proANP to be 
independently correlated with an increase in the heart rate.
Conclusion: In an RCT, liraglutide treatment in women with PCOS reduced levels of 
the cardiovascular risk biomarkers MR-proANP with 25% and MR-proADM with 6% 
(borderline significance) compared with placebo. The decrease in MR-proANP was 
independently associated with an increase in the heart rate.
Introduction
Women with polycystic ovary syndrome (PCOS) are 
challenged with a metabolic aspect of the syndrome 
as they have increased prevalence of overweight with 
central obesity and insulin resistance. They present with 
an accumulation of cardiovascular risk factors, but their 
actual risk of developing cardiovascular disease (CVD) is 
difficult to assess since long-term, prospective studies with 
well-defined diagnostic criteria are sparse. Nevertheless, 
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a meta-analysis recently reported that women with 
PCOS have a 30% increased risk of developing CVD and 
44% increased risk of coronary heart disease compared 
with age and BMI-matched healthy women (1). Besides 
lifestyle intervention and treatment with metformin, 
a  limited number of treatments that target the metabolic 
aspect of PCOS are available. As most PCOS patients 
are in the reproductive age and thus rather young, they 
rarely present with overt CVD; as a result, biomarkers 
of subclinical and early dysfunction of the heart and 
vascular endothelium could have a place in the work-up 
of patients. Adrenomedullin (ADM), atrial natriuretic 
peptide (ANP) and copeptin are all associated with CVD 
and part of the delicate system controlling fluid and 
hemodynamic homeostasis through vascular tonus and 
diuresis.
The vasodilating peptide ADM is ubiquitously 
expressed in the body, but secretion from vascular 
endothelium and smooth muscle cells is the main 
contributor to plasma levels (2). ADM is also considered 
an adipokine as it is expressed in adipocytes (3). Secretion 
of ADM is induced in response to inflammation, hypoxia 
and insulin resistance such that CVD and type 2 diabetes 
(T2D) are linked to increased levels of ADM (4, 5). The 
precursor prohormone midregional-pro-adrenomedullin 
(MR-proADM) is stable for measurement in the circulation 
and reflects ADM levels (6).
A- and B-type natriuretic peptides (NPs) (ANP and 
brain NP (BNP)) are synthesized in the cardiomyocytes 
from the pro-hormones midregional pro-A-type NP 
(MR-proANP) and N-terminal pro-B-type NP, and the 
NPs have a common receptor which is distributed widely 
(7). Both the intact peptides and the pro-hormones are 
released from the heart during hemodynamic stress as 
stretch of the cardiomyocytes during the development of 
heart failure, as well as during sympathetic stimulation 
(7). The NPs induce vasodilation and natriuresis, and 
reduce the renin–angiotensin–aldosterone system as well 
as the sympathetic nervous system, both activated in 
heart failure (7). Besides these main effects, the NPs can 
induce lipolysis, though this ability seems attenuated 
in obese individuals (8). Increased levels of the NPs are 
associated with CVD and early heart failure (9), but in 
contrast large cohort studies have shown that overweight 
and insulin resistance decrease levels of ANP (10). The 
preferred NPs to measure are the pro-hormones due to 
the fact that these assays are more stable and precise than 
assays measuring the intact peptides (7).
Copeptin is a splicing product that is released when 
vasopressin is activated. It is more stable for measurement 
than vasopressin itself and reflects vasopressin levels and 
thus responds to osmolality. Copeptin shows potential 
as a rule-out marker in combination with troponin in 
myocardial infarction, and increased copeptin levels in 
heart failure are associated with worsened outcome (11). 
Increased levels of copeptin have been demonstrated in 
obese individuals (12).
The three biomarkers have previously been evaluated 
in PCOS and healthy controls in cross-sectional studies, 
with contradicting results (13, 14, 15, 16, 17, 18). Weight 
loss and improved insulin sensitivity are cornerstones in 
the treatment of the metabolic syndrome, T2D and PCOS. 
Glucagon-like peptide 1 receptor agonists (GLP-1RA) were 
developed for treatment of hyperglycemia in T2D, but 
have additionally weight-reducing effect and have proven 
effective in smaller studies in women with PCOS (19). The 
LEADER study in high-risk patients with T2D reported 
that the GLP-1 RA liraglutide improved CVD outcomes 
(20). The mechanisms are not completely understood, 
though the available evidence suggests a beneficial effect 
on progression of atherosclerosis, endothelial dysfunction 
and inflammation. Based on this, we investigated the 
impact of 26  weeks of treatment with liraglutide in a 
PCOS cohort on the plasma levels of the cardiovascular 
biomarkers: MR-proADM, MR-proANP and copeptin in a 
double-blind placebo-controlled randomized clinical trial.
Subjects and methods
Design
The LIPT study was a double-blind placebo-controlled 
RCT. Women with PCOS were randomized in a 2:1 ratio 
to 1.8 mg liraglutide or placebo once daily for 26 weeks. 
Details of the study design and tolerability of the treatment 
have been described previously (21). In short, inclusion 
criteria were PCOS according to the Rotterdam criteria, 
BMI above 25 kg/m2 and/or insulin resistance defined as 
a fasting pro-insulin c-peptide above 600 pmol/L and use 
of non-hormonal contraception. Exclusion criteria were 
history of diabetes or CVD, treatment with hormonal 
contraceptives six weeks before or insulin-sensitizing drugs 
three months before randomization. The study protocol 
was approved by the Ethics Committee of Copenhagen 
(ID: H-2-2013-142), registered on www.clinicaltrials.gov 
(NCT02073929), and approved by the Danish Medicines 
Agency (EudraCT 2013-003862-15). The study was 
conducted in accordance with the Helsinki Declaration, 
monitored by the local GCP Unit, and oral and written 
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informed consents were obtained from participants before 
study-related procedures were performed.
Data collection
Body weight was measured in light clothes on a single 
calibrated scale. Waist circumference was measured 
between the lowest rib and the iliac crest. Consultation 
blood pressure was measured three consecutive times after 
ten minutes of rest in the sitting position. Blood samples 
were collected in the morning after ten hours overnight 
fast. A 75 g-oral glucose tolerance test was performed; 
blood samples were collected at 0, 30, 60 and 120 min. 
The measurements of HOMA2-IR and Matsuda index were 
calculated accordingly (22, 23). Routine blood analyses 
were performed immediately and samples for biomarkers 
were stored in tubes with EDTA at −80°C until analyses. 
Plasma MR-proADM, MR-proANP and copeptin were 
analyzed before the randomization key was broken with 
an automated immunofluorescence assay on a KRYPTOR 
platform (Thermo Fischer). Specifications: MR-proANP: 
Detection limit 2.1 pmol/L, intra-assay CV <3.5% and 
inter-assay CV <6.5%. MR-proADM: Detection limit 
0.05 nmol/L, intra-assay CV ≤10% and inter-assay CV 
≤20%. Copeptin measured as C-terminal pro-Vasopressin: 
Detection limit 0.9 pmol/L, intra-assay CV <15% and 
inter-assay CV <17%. Total testosterone was analyzed with 
mass spectroscopy (Waters UPLC-TQS LC–MS/MS system, 
Milford, USA), inter-assay CV 10%. Free testosterone 
was calculated from total testosterone and sex hormone 
binding globulin (SHBG). SHBG was analyzed with a 
sandwich chemiluminescence immunometric assay, inter-
assay CV 7%. Hemoglobin A1c (HbA1c) and fasting lipids 
were measured by routine methods. DXA whole beam fan 
scan (Hologic Discovery, Bedford, USA) was performed 
for whole body composition. MRI scans were performed 
on an Achieva 3.0 T MR-imaging system (Philips Medical 
Systems), and volumes of visceral and subcutaneous 
adipose tissue were measured in a 1-cm thick section at 
the L3 level.
The CONSORT statement for reporting clinical studies 
was used as a guidance for the study (24) and detailed 
information on design has previously been reported (21).
Statistical analyses
Change from baseline in the MR-proADM level was a 
secondary endpoint in the LIPT study. Power analysis 
performed on the primary endpoint, endogenous 
thrombin potential, dictated a sample size of 42:21 
(liraglutide:placebo) (21). To allow for 10% dropout, 
at least 70 patients should be randomized. A power 
analysis of the secondary endpoint MR-proADM was 
performed before randomization as described (25). With 
a sample size of 42:21 (liraglutide:placebo), an in-house 
s.d. of 0.03 nmol/L and a two-sided significance level of 
5%, we were able to detect a change in MR-proADM of 
0.025 nmol/L (equal to approximately 5% of the baseline 
values) with a power of 90%.
A mixed model with a repeated statement was used 
to test for differences between the treatment groups 
over time. Missing data at follow-up were handled by 
applying maximum likelihood in the mixed model 
procedure. The treatment groups were merged at baseline. 
Log2 transformation was applied when data were not 
Gaussian-distributed and consequently results from 
the mixed model are presented as ratios or percentage. 
Linear univariate and multiple regression analyses were 
performed in the liraglutide group with Δ-values of ΔMR-
proADM, ΔMR-proANP and Δcopeptin as dependent 
variables. Δ-Values were calculated as baseline subtracted 
from follow-up values, and β coefficient and Pearson’s 
correlation coefficient are reported. For the multiple 
regression analyses, 6 clinical relevant variables (BMI, 
Matsuda index, heart rate, visceral adipose tissue (VAT), 
eGFR and free testosterone) were chosen for analyses. Test 
for collinearity was performed (the ‘VIF’ command was 
applied) in all regression analyses. A P-value of 0.05 was 
considered significant. Statistical analyses were performed 
with SAS Enterprise Guide 7.1 (SAS Institute Inc., Cary, 
NC, USA).
Results
A total of 72 women were randomized in a 2:1 ratio 
allocating 42 women to liraglutide treatment and 21 to 
placebo. Seven participants dropped out during the study 
period (Fig. 1). The participants had a mean (s.d.) age of 
29.9 (6.1)  years and a BMI of 33.3 (4.9) kg/m2. The two 
groups were statistically comparable on all parameters at 
baseline.
Anthropometrics and body composition
On average (95% CI), the liraglutide group lost 5.2 kg 
(3.0–7.5, P < 0.001) equal to 5.6% body weight as mean 
difference compared with placebo. Systolic and diastolic 
blood pressure did not change during the study period, 
whereas heart rate increased with 6 bpm (2–10, P = 0.006) 
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in  the liraglutide group compared with placebo. We 
observed significant reductions in total fat and lean 
body mass as measured by DXA, as well as visceral 
and subcutaneous adipose tissues as measured by MRI 
(Table 1).
Biomarkers
At baseline, the median (IQR) levels of biomarkers in the 
whole group were MR-proADM 0.52 (0.45–0.56) nmol/L, 
MR-proANP 44.8 (34.6–56.7) pmol/L and copeptin 4.95 
(3.50–6.50) pmol/L. Mean differences between treatment 
groups over time showed a change in MR-proANP of −25% 
(95% CI −37 to −11, P = 0.001), a trend in MR-proADM 
of −6% (95% CI −11 to 2, P = 0.057) and no change in 
levels of copeptin in the liraglutide group compared with 
placebo (Fig. 2 and Table 1).
Biochemistry
We observed a reduction in mean difference of HbA1c 
in the liraglutide group compared with placebo, whereas 
there was no difference between treatment groups neither 
regarding markers of insulin resistance, HOMA2-IR and 
Matsuda index, nor eGFR. Fasting total, HDL and LDL 
cholesterol and triglycerides did not change during 
liraglutide/placebo treatment. Plasma SHBG increased 
and a trend toward a reduction in free testosterone 
in the liraglutide group compared with placebo was 
found (Table 1).
Regression analyses
Regression analyses between within-group changes (Δ) in 
ΔMR-proANP and all covariates presented in Table 1 were 
assessed for the liraglutide group. Tests for collinearity 
in the multiple regression analyses were negative. As 
ΔMR-proADM and copeptin did not change during the 
treatment period, regressions analyses were not performed. 
ΔMR-proADM did not correlate significantly in univariate 
analysis with any of the tested parameters. ΔMR-proANP 
correlated inversely with Δheart rate (β  −0.69, r 0.33, 
P = 0.03) and Δdiastolic blood pressure (β −0.89, r 0.34, 
P = 0.03). Multiple regression analyses with adjustment 
for BMI, free testosterone, Matsuda index, VAT, heart 
rate and eGFR showed ΔMR-proANP and heart rate to be 
independently correlated (Table 2).
Discussion
In this placebo-controlled RCT, evaluating the effect of 
liraglutide treatment on the cardiovascular biomarkers 
MR-proANP, MR-proADM and copeptin in women with 
PCOS, we observed a 25% reduction in MR-proANP, 
a trend toward a 6% reduction in MR-proADM and no 
Figure 1
CONSORT flow.
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change in copeptin levels. The reduction in MR-proANP 
was independently correlated with increased heart rate as 
seen during liraglutide treatment.
The borderline reduction in MR-proADM levels is in 
accordance with previous clinical studies demonstrating 
reduced MR-proADM levels after diet-induced weight loss 
(26) and gastric bypass surgery (27), although changes in 
MR-proADM and BMI did not correlated despite excessive 
weight loss (27). This is in accordance with our results of a 
6% borderline significant reduction in MR-proADM levels 
(P = 0.057) with no correlation to changes in BMI. ADM is 
also considered to be an adipokine as its expression has 
been demonstrated in human pre-adipocytes, stromal 
cells and activated macrophages in adipose tissue (28). 
Furthermore, ADM secretion from omental adipose tissue 
was increased in obese compared with lean women, and 
the secretion was correlated with features of the metabolic 
syndrome (28). Despite these reports and a substantial 
reduction in VAT in the present study, we were unable 
to find any correlations between MR-proADM levels and 
BMI or VAT, both at baseline and after weight reduction.
With respect to insulin resistance, previous studies are 
conflicting. During a euglycemic hyperinsulinemic clamp 
in obese individuals, plasma ADM increased in response 
to hyperinsulinemia (29). In contrast, considerable 
reduction in insulin resistance after gastric bypass was 
not associated with changes in ADM levels in obese 
individuals (27). We did not find any association between 
changes in MR-proADM levels and changes in insulin 
resistance as measured by HOMA2-IR and Matsuda index. 
To our knowledge, no clinical studies have previously 
studied the effect of liraglutide on MR-proADM levels. 
The study on gastric bypass has the closest resemblance 
as this procedure increased endogenous GLP-1 secretion 
considerably (27). Thus, the present and previous studies 
seem to acknowledge that weight loss does reduce ADM; 
however, whether this is driven by weight loss, change in 
insulin resistance or another factor remains unclear.
Low ANP levels and NPs in general have been linked 
to the development of hypertension, maybe by a direct 
action on the vessel wall (7, 29). Similarly, but with a 
potential different mechanism, ANP and other NP levels 
are low in obesity and seem restored to some extent after 
weight loss (7, 10, 26), although conflicting data exist, 
since unchanged ANP levels during excessive weight loss 
have also been reported (30). In obese individuals, the 
ratios of the expression of the activating to clearance 
receptors of ANP in adipose tissue have been found 
reduced with some degree of reversibility after weight 
loss (31).
GLP-1RA treatment in mice led to increased ANP 
levels, reduced blood pressure and increased natriuresis 
(32). In contrast, in human studies on T2D patients, 
liraglutide treatment led to reduction in both MR-proANP 
and blood pressure, but also increased natriuresis (33), 
which suggests that the antihypertensive effect of 
liraglutide might not be driven by MR-proANP levels, but 
rather to increased natriuresis. In line with this, Skov and 
coworkers (34) found a reduced tubular reabsorption in 
sodium during short-term studies on liraglutide on kidney 
function in T2D patients. In another clinical trial, studies 
on both short- and long-term effects of liraglutide in T2D 
patients found an increase in natriuresis, however no 
change in MR-proANP levels (35). In our study on women 
with PCOS, we found a similar reduction in MR-proANP 
as in T2D patients, whereas blood pressure remained 
unaltered. Unfortunately, we did not measure natriuresis. 
Both in the T2D study and in our PCOS study, the patients 
lost a considerable amount of weight, including fat mass 
Table 2 Multiple regressions between changes in metabolic 
parameters after 26 weeks of treatment in the liraglutide 
group in women with PCOS.
Liraglutide group ΔMR-proANP β (s.e.) P
ΔBMI −1.40 (2.05) 0.50
ΔFree testosterone −462 (240) 0.06
ΔMatsuda index −0.75 (2.46) 0.76
ΔVAT −0.02 (0.13) 0.88
ΔHeart rate −0.77 (0.36) 0.045
ΔeGFR 0.29 (0.39) 0.46
Δ, changes during treatment period; MR-proANP, midregional proatrial 
natriuretic peptide; r, Pearson’s correlation coefficient; s.e., standard 
error; VAT, visceral adipose tissue.
Figure 2
Effect of liraglutide or placebo treatment on 
levels of MR-pro-adrenomedullin, copeptin, and 
MR-proANP. Median and interquartile range 
before and after 26 weeks of treatment.
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and VAT. This could potentially lead to an increase in 
MR-proANP levels due to the above-mentioned shift in 
activating and clearance receptors of NPs, but did not 
seem to occur in this cohort.
Liraglutide is known to increase heart rate with 
approximately 3 bpm (36), by yet unknown mechanisms, 
and accordingly we observed an increase of 6 bpm during 
liraglutide treatment in our PCOS cohort. GLP-1 receptors 
have been identified in the human heart both in the sinus 
node (37) and the atria (32). In our study, the reduction 
in MR-proANP levels correlated strongly with the increase 
in the heart rate, and remained independently correlated 
after adjustment for changes in BMI, VAT, Matsuda index, 
free testosterone and eGFR. From a previous cross-sectional 
study on 98 PCOS women (38), we were able to extract 
data on MR-proANP and heart rate, and could reproduce 
the significant negative correlation, between log2 
MR-proANP and heart rate (β = −0.02 (s.e. 0.004), r 0.43, 
P < 0.001) (unpublished data). A mechanism which could 
affect circulating MR-proANP levels during liraglutide 
treatment is an increased natriuresis and decreased 
extracellular volume. These changes in natriuresis and 
extracellular volume have been demonstrated together 
with 20% decrease in MR-proANP levels and a 6.5-bpm 
increase in the heart rate in T2D patients after liraglutide 
treatment (39), and liraglutide infusion increased heart 
rate and natriuresis in healthy individuals; however, 
neither ANP nor BNP levels changed (40). We did not 
address these issues in our PCOS population. The LEADER 
study demonstrated improvement in CVD outcomes 
despite an increase in the heart rate of 3 bpm (20).
Regarding testosterone, studies in other populations 
and a study administering testosterone therapy in women 
with hypoandrogenemia point to an inverse correlation 
between NPs and testosterone (41, 42). We have previously 
reported a significant inverse correlation in a case-control 
study (38), but the association vanished after adjustment 
for BMI, age, pro-insulin c-peptide, LDL cholesterol, eGFR 
and systolic blood pressure. Based on these findings, the 
relatively low endogenous testosterone levels in women 
with PCOS compared with men do not seem to have any 
major influence on MR-proANP levels.
To the best of our knowledge, this is the first report 
on the effect of liraglutide treatment on circulating 
levels of copeptin in humans. As levels of copeptin are 
increased in individuals with obesity and IR (12, 43), a 
reduction in weight would favor a reduction in copeptin 
levels in our PCOS cohort, whereas a possible liraglutide-
induced diuresis would favor an increase through osmotic 
stimuli. In rats, increased and decreased vasopressin levels 
induced by injections of vasopressin or increased fluid 
intake in lean and obese rats (44) demonstrated increased 
vasopressin levels to induce increased glycemia in lean 
rats and increased IR in obese rats. Large population 
studies report that high copeptin levels might predict 
the development of T2D (11). We could not demonstrate 
an otherwise hypothesized reduction in copeptin during 
liraglutide treatment. Whether copeptin levels are 
influenced by a counter regulation to a hypothesized 
liraglutide-induced natriuresis is a question for further 
investigation, or perhaps our participants were too young 
and therefore without subclinical CVD.
Limitations: 24 h ambulatory blood pressure and heart 
rate recordings would have given more precise estimates, 
but were not performed. A pre-study power analysis based 
on MR-proADM was performed; however, the expected 
change in MR-proADM was not met, and the study 
might thus be underpowered to some degree. We used 
the CONSORT statement as a guideline (24) for reporting 
a clinical study and one issue needs attention: Clinical 
biomarkers have an inherent and large biological and 
analytical variation. The analytical variation is reflected 
in usually a rather large CV of the assay, especially 
the inter-assay CV, whereas the biological variation is 
reflected in day-to-day changes in the individual. With 
regard to MR-proANP measurements (and probably 
also measurements of MR-proADM and copeptin), such 
rather large biological variations have been reported, 
and estimates for clinically relevant changes in terms 
of percent changes over time have been suggested (45). 
The small changes that we observed are less than these 
estimates, which weaken our results, and might be 
the reason for the diversity of findings on MR-proANP 
measurements discussed above. In order to minimize this 
potential bias, we analyzed samples from one individual 
in the same assay (avoiding inter-assay CV), and used the 
placebo-controlled study design.
One could argue that we should have measured BNP 
and not ANP, since BNP is the established biomarker for 
evaluating heart failure. ANP and BNP seem to be secreted 
and metabolized in a quite similar fashion, and they 
have the same receptor (7). We studied ANP since the 
MR-proANP has the longest plasma half-lifetime which is 
translated into the most robust assay performance within 
the NP technology. This is also reflected in the fact that 
most studies focusing on metabolic disturbances and the 
effect of liraglutide have used MR-proANP measurements. 
We did not measure other established biomarkers as 
galactin-3 or troponins since these biomarkers mainly 
reflect cardiac fibrosis and necrosis, respectively, and 
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we did not expect to find changes in such parameters in 
our cohort of relatively young PCOS women.
Conclusion
During 26 weeks of treatment with 1.8 mg/day liraglutide 
in a PCOS cohort, we saw a 25% reduction in MR-proANP 
levels and a trend toward a 6% reduction in MR-proADM, 
whereas copeptin levels did not change compared with 
placebo. The reduction in MR-proANP was associated with 
an increase in the heart rate, and the mechanism behind 
we can only speculate on, but taking current literature 
together, we believe that these changes represent a signal 
of beneficial metabolic adaptations. Further research works 
regarding the direct effect of liraglutide on MR-proANP 
levels and natriuresis are warranted.
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